Re: Fwd: FW: link for cobalt levels following mB12 injections, autism cohort

[Guest guest]

Thank you. I agree that it works. My son has been taking a prescribed dosage

of B12 sublingual for 10 years and it works.

Glenda

>

>

>

>

>

> ____________________________________

>

>

>

>

> From: BADILLO9@...

> Sent: Tuesday, May 04, 2010 5:54 AM

> To: drdavid@...

> Subject: Re: FW: link for cobalt levels following mB12 injections, autism

> cohort

>

>

>

>

>

> To the editor:

>

> While I have a great deal of respect for the overall work of and Mark

> Geier, their recent article “An Autism Cohort Study of Cobalt Levels

> Following Vitamin B12 Injections†misuses findings to create an unjustified

> level of fear about the use of methylcobalamin (methylB12) to treat autism.

> Since this treatment is widely recognized as being effective in a

> significant number of autistic individuals, it is critical to not allow a

> scientifically flawed paper to undermine its use. The authors found a mean

> plasma level of cobalt of 0.82 ug/liter for subjects receiving methylB12

> injections, which corresponds to a concentration of 14 nM, and they found

> that neuroblastoma cells exhibit a toxic response to cobalt(II)nitrate

> hexahydrate with an LC50 of 559 uM. As a first significant problem, their

> comparison of cobalt in vitamin B12 with the free heavy metal form of

> cobalt

> is an inappropriate and misleading comparison. It would be as if

> supplements

> containing vitamin B12 actually contained the heavy metal cobalt, which is

> obviously not the case. The authors have an obligation to characterize the

> chemical form of cobalt, which is highly likely to be overwhelmingly in the

> form of vitamin B12, not in the form of free cobalt. Secondly, the

> difference between the plasma concentration and the toxic concentration is

> 40,000-fold, but the authors fail to make this comparison. If indeed the

> plasma form of cobalt is in the form of vitamin B12, the difference in free

> cobalt concentrations is actually much higher than 40,000-fold. These

> discrepancies make this article scientifically invalid and as such it

> should

> be withdrawn. Studies directed toward identifying optimal dosing regimens

> for methylB12, with minimal toxicity, are indeed important. Unfortunately,

> this is not such a study.

>

> Sincerely,

> C. Deth, PhD

>

> Professor of Pharmacology

> Northeastern University

> 360 Huntington Avenue

> Boston, MA 02115

> USA

>